StockData
INVO Fertility, Inc. logo

INVO Fertility, Inc. (IVF) company profile

IVFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$1.98−0.20 (-9.17%)

Close on Nov 18, 2026Market cap $4.96MP/E –Yield –

About INVO Fertility

Surgical & Medical Instruments & Apparatus, SIC 3841

The company is a healthcare and biotechnology enterprise that focuses on fertility services and therapeutics. Its core operational segments comprise fertility clinic services and therapeutics development. Through its clinic operations and product offerings, the organization provides reproductive healthcare treatments, fertility solutions, and related therapeutic innovations. It conducts operations and manages ventures linked to entities such as NAYA Therapeutics and fertility clinics, including the Wisconsin Fertility Institute. Its principal customers consist of individual fertility patients seeking reproductive care, clinical practitioners, and partner healthcare organizations requiring reproductive technologies and specialized therapeutic solutions.

Regarding geographic footprint and organizational scale, the text indicates operational interests and joint venture activities located in the United States, specifically within Georgia, Alabama, and Wisconsin through local joint ventures and clinic acquisitions. The provided text contains no details concerning the total number of medical facilities, retail locations, additional international countries of operation, or the exact location of the corporate headquarters.

Summary of the business section of INVO Fertility's latest annual report, written by StockData.

Company profile

Company

Legal name
INVO Fertility, Inc.
Headquarters
Sarasota, FL
Address
5582 Broadcast Court 34240
Phone
(978) 878-9505
Employees
14, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
M&K CPAS, PLLC, The Woodlands, TX

Stock & identifiers

Ticker
IVF
Former tickers
NAYA until Apr 30, 2025; INVO until Nov 8, 2024
Exchange
Nasdaq
IPO date
Nov 2, 2020
Shares outstanding
3M, Aug 14, 2026
Public float
$2.19M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-40 reverse, Jun 2, 2026; 1-for-5 reverse, Mar 27, 2026; 1-for-8 reverse, Nov 28, 2025; 1-for-3 reverse, Jul 21, 2025; 1-for-13 reverse, Apr 30, 2025; 1-for-12 reverse, Mar 18, 2025; 1-for-20 reverse, Jul 28, 2023; 1-for-20 reverse, Aug 13, 2020
SEC CIK
1417926
CUSIP
44984F880
ISIN
US44984F8804
FIGI
BBG000GHH9P9
Share class FIGI
BBG001T2XX39
EIN
20-4036208

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Steve ShumChief Executive Officer, Director674
Terah Renee KrigsvoldChief Financial Officer1
Andrea GorenChief Financial Officer129,227
Matthew K. SzotDirector0
Trent D. DavisDirector49
Barbara RyanDirector46
Rebecca MessinaDirector33

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$430.86K$389.58K$180.84K$0–
FY2024$260.00K$256.23K$181.68K$10–
FY2023$232.68K$202.08K$222.13K$16–
FY2022$502.00K$53.05K$462.91K$12–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Steven Shum
Chief Executive Officer (1)
$278.76K$75.00K$52.11K$25.00K$430.86K+66%
Terah Krigsvold
Chief Financial Officer
$250.00K$50.00K$36.47K–$336.47K–
Andrea Goren
Chief Business Officer Former Chief Financial Officer
$218.76K$20.00K$43.77K–$282.53K+31%
Dr. Daniel Teper
Former President (8)(9)
$260.00K–––$260.00K+89%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“of December 31, 2025, INVO employed 14 full time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 18, 2026Late filingNotification of late filing
Apr 29, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2026Late filingNotification of late filing
Feb 24, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 17, 2025Late filingNotification of late filing
Sep 5, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 6, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 15, 2025Late filingNotification of late filing
Apr 18, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 14, 2025Name changeName changed from NAYA Biosciences, Inc. to INVO Fertility, Inc.
Mar 31, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2025Late filingNotification of late filing
Jan 16, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2024Late filingNotification of late filing
Oct 15, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 15, 2024Name changeName changed from INVO Bioscience, Inc. to NAYA Biosciences, Inc.
Sep 20, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 20, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2024Late filingNotification of late filing
Jan 16, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 11, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 13, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 30, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 30, 2023Late filingNotification of late filing
Jan 23, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 12, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 7, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 12, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?